SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : The Stock for 1999(Polymedica)PLMD(Medical Supply Co.) -- Ignore unavailable to you. Want to Upgrade?


To: Sam who wrote (2823)9/4/1999 12:55:00 PM
From: Proton  Read Replies (1) | Respond to of 3414
 
Re: Analysis of Secondary Offering Financial Impact

Here, warts and all. If you pick at the assumptions or calculations, please offer alternatives (if I want whining, I'll go to my toddlers and teens!).

FY 2000 (per share new basis):
EPS dilution: (0.23)
Interest reduction: 0.09
Investment income: 0.07
Net effect on EPS: (0.07)

FY 2001:
EPS dilution: (0.32)
Interest reduction: 0.18
Investment income: 0.14
Net effect on EPS: 0.00

Assumptions:

1. "EPS Dilution" and "Net effect" based on current fiscal year earnings of 1.06/share and next year's 1.35/share (Zacks).

2. Working capital invested in 1-year T-bills yield to maturity of 5.20% (September 3 close).

3. Interest reduction and investment income accrue for one-half of FY2000, but EPS dilution based on entire FY.

4. No depletion of working capital within scope of analysis (in reality, one expects that management will make acquisitions or capital purchases, and we should expect those to have a greater return than the T-bill rate... assumptions 2 & 3 give a basis for calculating the impact of $30+ million of new cash).

5. No amortization of Guaranteed Senior Secured Notes due January 31, 2003 (10.9% coupon).

6. Shares issued & outstanding (from the S-3)
Pre-offering: 9,319,913
Post-offering: 12,219,913

7. Offering price $26/share (depends on market reaction to S-3)